AGI-14100 is a novel orally bioavailable mIDH1 inhibitor. Preclinical trials of AGI-14100 for the treatment of primary human myeloid leukemia therapy have been underway since 2013. References:
纯度：≥98%
CAS：1448346-43-7
m.cnreagent.com